|
|
???tair.name??? >
???browser.page.title.author???
|
"majem majem m"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
|
John, T.;Groh�, C.;Goldman, J.W.;Shepherd, F.A.;de, Marinis F.;Kato, T.;Wang, Q.;Su, W.-C.;Choi, J.H.;Sriuranpong, V.;Melotti, B.;Fidler, M.J.;Chen, J.;Albayaty, M.;Stachowiak, M.;Taggart, S.;Wu, Y.-L.;Tsuboi, M.;Herbst, R.S.;Majem, Majem M. |
| 國立成功大學 |
2023 |
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
|
Tsuboi, M.;Herbst, R.S.;John, T.;Kato, T.;Majem, Majem M.;Groh�, C.;Wang, J.;Goldman, J.W.;Lu, S.;Su, W.-C.;De, Marinis F.;Shepherd, F.A.;Lee, K.H.;Le, N.T.;Dechaphunkul, A.;Kowalski, D.;Poole, L.;Bolanos, A.;Rukazenkov, Y.;Wu, Y.-L. |
| 國立成功大學 |
2021 |
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
|
Herbst, R.S.;Garon, E.B.;Kim, D.-W.;Cho, B.C.;Gervais, R.;Perez-Gracia, J.L.;Han, J.-Y.;Majem, Majem M.;Forster, M.D.;Monnet, I.;Novello, S.;Gubens, M.A.;Boyer, M.;Su, W.-C.;Samkari, A.;Jensen, E.H.;Kobie, J.;Piperdi, B.;Baas, P. |
| 國立成功大學 |
2020 |
Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study
|
Herbst, R.S.;Garon, E.B.;Dong-Wan, K.;Cho, B.C.;Perez-Gracia, J.L.;Ji-Youn, H.;Arvis, C.D.;Majem, Majem M.;Forster, M.D.;Monnet, I.;Novello, S.;Szalai, Z.;Gubens, M.A.;Wu-Chou, S.;Ceresoli, G.L.;Samkari, A.;Jensen, E.H.;Lubiniecki, G.M.;Baas, P. |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
